Research paperThe assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases
Introduction
Arthritis involves the progressive loss of normal joint structure and function resulting from the erosion and loss of articular cartilages in diseases such as rheumatoid arthritis (RA) and osteoarthritis. The consequences of this destructive process can be viewed radiologically by examining joint space narrowing. It is of importance to be able to accurately detect the loss of articular cartilage as a process not only as an outcome. This may be possible by a methodology that permits measurement in body fluids of degradation products resulting from the cleavage of cartilage-specific macromolecules which are components of the extracellular matrix and are progressively destroyed in arthritis (Poole, 2001, Poole, 2003). One of these molecules is type II collagen. This is the major component of hyaline cartilage matrix that forms an extensive fibrillar network that endows cartilage with its tensile strength (Poole, 2001).
We have shown in rheumatoid arthritis (Dodge and Poole, 1989) and osteoarthritis (Hollander et al., 1994, Billinghurst et al., 1997, Dahlberg et al., 2000, Wu et al., 2002) that degradation of type II collagen is increased, involving excessive cleavage of this molecule by collagenases. As a consequence, cleavage products produced by collagenases are excessively released from cartilage and can be measured in culture medium (Billinghurst et al., 1997, Dahlberg et al., 2000). Previously, we prepared an antibody that recognizes the cleavage of type II collagen by collagenases in cartilage and which was used to demonstrate increased collagenase activity both in cartilage (Billinghurst et al., 1997) and in culture media (Dahlberg et al., 2000, Billinghurst et al., 1997). Although articular cartilages do not contain type I collagen, this antibody cross-reacted with this molecule when cleaved by collagenases (Billinghurst et al., 1997).
To enable us to selectively detect cleavage of only type II collagen, we have prepared a monoclonal antibody which provides this specificity. In this paper, we describe the specificity of the antibody C2C (previously known as COL2-3/4CLong mono) and its use in an ELISA to detect collagenase-generated cleavage products of type II collagen in body fluids in health and arthritis.
Section snippets
Patients, body fluids and general assays
We have studied body fluid samples from patients with rheumatoid arthritis (RA) as well as from a nonarthritic population of hospital employees and friends of patients who volunteered blood samples. Informed consent was obtained after the nature and possible consequences of the studies had been fully explained. Patients were classified in accordance with the guidelines of the American College of Rheumatology (Arnett et al., 1987). The ages, sexes and clinical characteristics of patients and
Monoclonal antibody C2C (COL2-3/4 CLong mono) and its specificity
An antibody with an IgG1 isotype was identified by Western blotting. It reacted strongly with the α chain of type II collagen but only following cleavage by collagenases MMP-1, or -13 (Fig. 2B, lane 5, 6 and 7). Reactivity was with the TCA or 3/4 piece. There was no reactivity with the α chain or the TCB or 1/4 piece observed by Coomassie staining (Fig. 2A). Secondary degradation products of the TCA piece of type II collagen can be seen in the Western blot in (Fig. 2B) lanes 6 and 7. The
Discussion
The immunoassay described here offers the opportunity to examine in vivo the degradation of articular cartilage by measuring degradation products resulting from the cleavage of cartilage type II collagen by collagenase. A prior report of such an assay that is specific for the cleavage of the triple helix of type II collagen by collagenase has already been described (Downs et al., 2001). This is a sandwich assay that employs a monoclonal antibody to the collagenase-generated cleavage neoepitope
Acknowledgements
This study was funded by Shriners Hospitals for Children, National Institute of Ageing, National Institutes of Health, Canadian Institutes of Health and Canadian Arthritis Network (to ARP). RCB received a fellowship from the Fonds de la Recherche en Santé du Québec.
References (18)
- et al.
Collagen type II c-telopeptide fragments as an index of cartilage degradation
Bone
(2001) - et al.
Elevation of a collagenase generated type II collagen neoepitope and a proteoglycan epitope in synovial fluid following induction of joint instability in the dog
Osteoarthr. Cartil.
(2002) - et al.
Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA
J. Immunol. Methods
(2001) Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis
Rheum. Dis. Clin. North Am.
(2003)- et al.
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
Arthritis Rheum.
(1987) - et al.
Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage
J. Clin. Invest.
(1997) - et al.
The association between cartilage collagenase activity measured in serum and progression of kneen osteoarthritis in patients with and without evidence of generalized disease
Arthritis Rheum.
(2002) Separation of type III collagen from type I collagen by pepsin by differential denaturation and renaturation
Biochem. Biophys. Res. Commun.
(1978)- et al.
Collagenase-mediated cleavage of type II collagen is selectively enhanced in osteoarthritis cartilage and can be arrested with a synthetic inhibitor which spares collagenase-1 (MMP-1)
Arthritis Rheum.
(2000)
Cited by (123)
Immobilization by 21 days of bed rest results in type II collagen degradation in healthy individuals
2024, Osteoarthritis and CartilageAssociation of synovial fluid and urinary C2C-HUSA levels with surgical outcomes post-total knee arthroplasty
2024, Osteoarthritis and CartilagePd@Pt nanoparticle-linked immunosorbent assay for quantification of Collagen type II
2023, Analytica Chimica ActaType II collagen
2023, Biochemistry of Collagens, Laminins and Elastin: Structure, Function and Biomarkers, Third EditionDual targeting single arrow: Neutrophil-targeted sialic acid-modified nanoplatform for treating comorbid tumors and rheumatoid arthritis
2021, International Journal of Pharmaceutics
- 1
Present address: St. Lawrence College, Kingston, Ontario, Canada.